Find all the latest information in myeloproliferative neoplasms, arranged by types, translocations, and mutations. Listed below are recently updated categories.
5-year results from the PROUD-PV and CONTINUATION-PV studies
Ropeginterferon alfa-2b is a novel pegylated recombinant interferon, approved in the EU as monotherapy for the treatment of adults with...
Clinical factors associated with response to ruxolitinib in patients with myelofibrosis
A dysregulated Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is...
Ropeginterferon alfa-2b is effective and safe in patients older than 60 years with PV
As discussed in our last editorial theme, the pegylated forms of interferon-alpha improve treatment compliance...
Combining interferon-α and arsenic for the treatment of JAKV617F mutant MPN
Myeloproliferative neoplasms (MPN) are a group of stem cell diseases that are typified by an increased production of...
Predicting transition in prefibrotic myelofibrosis
With the 2016 revision to the World Health Organization classification of myeloproliferative neoplasms (MPN), patients with prefibrotic primary...
Applying prognostic models for myelofibrosis in practice
The review by How et al. covers established and emerging prognostic models for PMF.
The practical use of myelofibrosis genomics in a clinical setting
Myelofibrosis (MF), a subtype of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), is characterized by Janus...
Understanding the pathology of MPN: The value of in vivo and in vitro models
Among chronic Philadelphia-negative myeloproliferative neoplasms (MPN), polycythemia vera (PV) is considered the most...
Epigenetic modifier mutations
JAK2 driver mutations
JAK2 exon 12 deletions
JAK2 exon 12 insertions
MPL driver mutations
Chronic eosinophilic leukemia
Chronic neutrophilic leukemia
Tumor suppressor mutations